Abstract
Background International literature suggests that disadvantaged groups are at higher risk of morbidity and mortality from SARS-CoV-2 infection due to poorer living/working conditions and barriers to healthcare access. Yet, to date, there is no evidence of this disproportionate impact on non-national individuals, including economic migrants, short-term travellers, and refugees.
Methods We analysed data from the Italian surveillance system of all COVID-19 laboratory-confirmed cases tested positive from the beginning of the outbreak (20th of February) to the 19th of July 2020. We used multilevel negative-binomial regression models to compare the case-fatality rate and the rate of admission to hospital and intensive care unit (ICU) between Italian and non-Italian nationals. The analysis was adjusted for differences in demographic characteristics, pre-existing comorbidities, and period of diagnosis.
Results We analysed 213,180 COVID-19 cases, including 15,974 (7.5%) non-Italian nationals. We found that, compared to Italian cases, non-Italian cases were diagnosed at a later date and were more likely to be hospitalised [(adjusted relative risk (ARR)=1.39, 95% confidence interval (CI): 1.33-1.44)] and admitted to ICU (ARR=1.19, 95% CI: 1.07-1.32), with differences being more pronounced in those coming from countries with lower HDI. We also observed an increased risk of death in non-Italian cases from low-HDI countries (ARR=1.32, 95% CI: 1.01-1.75).
Conclusions A delayed diagnosis in non-Italian cases could explain their worse outcomes compared to Italian cases. Ensuring early access to diagnosis and treatment to non-Italians could facilitate the control of SARS-CoV-2 transmission and improve health outcomes in all people living in Italy, regardless of nationality.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding outside the routine institutional funds were used to carry out this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The scientific dissemination of COVID-19 surveillance data was authorised by the Italian Presidency of the Council of Ministers on the 27th of February 2020 (Ordinance n. 640).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵§ COVID-19 working group Maria R. Castrucci, Alessandra Ciervo, Corrado Di Benedetto, Stefania Giannitelli, Paola Stefanelli, Marco Tallon, Roberta Urciuoli (Istituto Superiore di Sanità); Regional representatives: Manuela Di Giacomo (Abruzzo); Michele La Bianca (Basilicata); Anna D. Mignuoli (Calabria); Angelo D’Argenzio (Campania); Erika Massimiliani (Emilia-Romagna); Tolinda Gallo (Friuli Venezia Giulia); Paola Scognamiglio (Lazio); Camilla Sticchi (Liguria); Danilo Cereda (Lombardia); Daniel Fiacchini (Marche); Francesco Sforza (Molise); Maria G. Zuccaro (P.A. Bolzano); Pier P. Benetollo (P.A. Trento); Daniela Tiberti (Piemonte); Maria Chironna (Puglia); Maria A. Palmas (Sardegna); Salvatore Scondotto (Sicilia); Lucia Pecori (Toscana); Anna Tosti (Umbria); Mauro Ruffier (Valle D’Aosta); Filippo Da Re (Veneto).
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos